China Biologic Products (NASDAQ:CBPO)

BEIJING, April 2, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its Board of Directors has adopted a series of measures to improve the Company's corporate governance, especially to enhance the independence and transparency of the Board.

The Board elected Mr. David (Xiaoying) Gao as Chairman of the Board of Directors with effect on March 30, 2012. Mr. Gao succeeds Ms. Siu Ling Chan who served for more than five years as China Biologic's Chairwoman. Ms. Chan will remain as a Director on the Board.

In addition, the Board, in accordance with Article III of the Company's Amended and Restated Bylaws, increased the size of the Board from seven to nine directors. The Board intends to appoint two additional independent directors to fill the vacancies created by such increase. The Governance and Nominating Committee of the Board is authorized to make recommendations to the Board regarding independent director candidates.

On October 6, 2011, Dr. Xiangmin Cui resigned from his positions as a director of China Biologic Products, Inc. (the “Company”), a member of the Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee of the Company and the Chairman of the Compensation Committee, effective immediately. Mr. Cui’s resignation was due to personal reasons and not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Cui will serve as an independent consultant for the Company.